Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

BioMarin Pharmaceutical Inc. BMRN

Healthcare — Biotechnology

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
4.32
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — — — — 2 1 — 1 — — — 1
Insider Ownership
1.21%

Capital & Financial Ratios

Market Cap
12,380.00
Revenue
3,406.61
Net Income
72.97
Free Cash Flow
724.81
Net Debt
3,312.14
Current Ratio
2.39
Debt/Equity
0.66
P/E ratio
168.26
P/S ratio
3.63
P/B ratio
1.96
Past 5Y EPS Growth
—
This Y EPS Growth
178.43%
Next Y EPS Growth
32.55%
Next 5Y EPS Growth
63.35%
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
—
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 1,073.81 1,137.71 1,560.61 874.01
Receivables 633.70 660.54 908.21 1,061.05
Inventory 1,107.18 1,232.65 1,298.88 1,782.52
Other 141.39 201.53 185.78 254.05
2,956.09 3,232.43 3,953.49 3,971.62
2023 2024 2025 Q'26
Payables 683.15 606.99 759.03 1,005.79
ST’ Debt 493.88 — — 658.20
Other — — — —
1,177.02 606.99 759.03 1,664.00
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Book Value ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 766.21 989.71 — —
—
’25 745.15 825.41 776.13 874.56
3,221.25
’24 648.83 712.03 745.74 747.31
2,853.92
’23 596.42 595.28 581.33 646.21
2,419.23
’22 519.36 533.80 505.34 537.54
2,096.04
’21 486.03 501.69 408.74 449.81
1,846.28
’20 502.07 429.49 476.78 452.12
1,860.46
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 220.65 168.11 — —
—
’25 174.39 185.27 368.69 99.64
827.99
’24 46.97 118.76 221.48 185.63
572.84
’23 (73.93) 70.06 135.65 27.48
159.26
’22 (45.43) 56.23 158.32 6.79
175.90
’21 113.51 82.78 97.06 11.18
304.54
’20 (15.19) 27.74 86.21 (13.38)
85.37
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 199.73 133.86 — —
—
’25 157.63 167.90 334.94 56.55
717.02
’24 22.87 96.92 200.31 165.33
485.42
’23 (98.70) 47.33 112.23 (9.21)
51.65
’22 33.89 28.19 121.85 (36.25)
147.69
’21 85.26 56.53 76.70 (33.18)
185.31
’20 7.95 (5.75) 66.05 (53.25)
15.01
in millions of $

EPS

Mar Jun Sep Dec Year
’26 0.54 0.23 — —
—
’25 0.95 1.23 (0.16) (0.24)
1.80
’24 0.46 0.55 0.55 0.64
2.21
’23 0.27 0.29 0.21 0.11
0.87
’22 0.63 0.15 (0.04) 0.00
0.75
’21 0.09 0.07 (0.20) (0.32)
(0.35)
’20 0.44 (0.16) 4.01 0.12
4.53

Target Price Range

High
‡‡‡‡‡
‡‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.6
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 70.73 76.02 61.15 50.76 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 109.56 117.77 99.25 73.51 — — —
High Price
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3,082 3,401 3,040 3,221 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.68 0.71 0.94 1.00 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,096.04 2,419.23 2,853.92 3,221.25 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 76.00% 78.01% 79.67% 77.73% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 149.58 188.56 541.76 482.48 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.14% 7.79% 18.98% 14.98% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 141.56 167.65 426.86 348.90 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 105.01 95.16 88.08 74.76 — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 11.31 12.88 15.02 16.80 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 0.76 0.89 2.25 1.82 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.95 0.85 3.01 4.32 ‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.15) (0.57) (0.46) (0.58) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.80 0.28 2.55 3.74 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 24.85 26.36 29.77 31.74 ‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 185.27 187.83 190.03 191.79 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡‡ ‡‡‡ 130.66 110.17 29.21 32.65 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡ 8.89 7.61 4.38 3.54 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4.05 3.72 2.21 1.87 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 8.80 7.62 4.36 3.39 ‡‡‡ ‡‡‡‡ ‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 124.87 356.84 25.63 15.24 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 175.90 159.26 572.84 827.99 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (28.21) (107.61) (87.42) (110.97) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 147.69 51.65 485.42 717.02 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2,162.57 1,779.06 2,625.44 3,194.46 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1,093.02 1,086.97 595.14 597.18 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (198.52) 13.16 (542.57) (963.43) — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 4,603.16 4,951.55 5,657.99 6,087.00 — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.29% 2.54% 6.17% 4.79% — — —
ROA
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 2.28% 2.34% 5.92% 5.00% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 3.19% 3.51% 8.05% 5.94% — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

BioMarin Pharmaceutical (BMRN), a rare-disease specialist, has delivered robust revenue growth of 15% CAGR from 2016-2024, reaching $2.85 billion, fueled by blockbusters like Voxzogo for achondroplasia and Palynziq for PKU. Operational efficiency shines with revenue per employee doubling to $939,000 and gross margins rebounding to 79.7%, supporting projected acceleration to $3.65 billion by 2027. Yet, the stock trades at a stark discount—near the lowest analyst targets, 58% below average, and 100% below highs—decoupling from 155% revenue gains and a cash-rich balance sheet after slashing debt 45%.

Profitability is inflecting sharply: EBT swung from -$831 million to +$542 million, ROE hit 8.1% (projected 14.6% in 2025), and FCF per share surged 810% to $2.55, funding R&D without dilution. Valuation multiples scream undervaluation—P/E contracting to 13x by 2027 amid 90% EPS growth, P/S at 4.4x versus historical peaks, and EV/FCF at 26x post-turnaround. Modest insider selling (no buys) amid stable shares hints at profit-taking, not alarm, in a $11 billion market cap.

This lag versus fundamentals—stock range-bound at $60-100 despite 79% book value growth—signals re-rating potential as Voxzogo expands and pipeline assets like BMN 307 advance. Analysts forecast 28% net income CAGR through 2027, with 50-100% upside to targets, positioning BMRN as a mispriced growth powerhouse in biotech’s volatility.

Read full commentary →

BioMarin Pharmaceutical Inc. (BMRN) Latest News

News by impact score

Fine-tune

19 Sep

4 , 4:10 AM
BioMarin’s VOXZOGO wins approval or strong data in hypochondroplasia and the company adds a new R&D leader, shifting its investment narrative toward expanded growth and pipeline strength. VOXZOGO hypochondroplasia success plus new R&D hire mark major product expansion and leadership change that can materially lift BioMarin’s trajectory.

3 , 10:12 AM
BioMarin Pharmaceutical draws fresh investor attention amid pipeline progress and market positioning updates that could influence upcoming catalysts and stock performance. Pipeline updates and market positioning create moderate influence on financial outlook and investor sentiment without fundamentally altering long-term trajectory.

18 Sep

4 www.marketbeat.com, 1:02 PM
BioMarin Pharmaceutical targets synergies with Amicus Therapeutics while VOXZOGO approaches a $1 billion sales milestone. VOXZOGO nearing $1B sales plus Amicus synergies point to major revenue growth and strategic expansion for BioMarin.

12 Sep

3 , 1:02 PM
BioMarin Pharmaceutical settled its global patent dispute with Ascendis, prompting a 5% rise in its shares. Patent settlement ends litigation risk and lifts shares 5%, producing moderate operational relief.

9 Sep

4 , 9:05 AM
BioMarin announces positive Phase 3 VOXZOGO (vosoritide) study results in hypochondroplasia published in NEJM Evidence. Positive Phase 3 results expand VOXZOGO market potential and strengthen BioMarin pipeline.

4 Sep

4 stocktwits.com, 3:24 AM
BioMarin stock crashes in worst day ever. Martin Shkreli calls shares very cheap and floats buyout possibility. Shkreli buyout speculation amid crash introduces major M&A-driven market volatility and valuation shifts for BioMarin.

3 , 12:26 PM
BioMarin secured 20% U.S. royalties on Yuviwel by monetizing a rival product rather than blocking it. Royalties on Yuviwel add a revenue stream that may influence financials without fundamentally shifting BioMarin trajectory.

3 , 3:08 AM
Ascendis Pharma settled a patent dispute and secured Canadian reimbursement backing for Yorvipath. Patent settlement and reimbursement win for Ascendis Yorvipath opens Canadian market access that may pressure BioMarin competitive positioning in related indications.

3 Sep

4 , 12:28 PM
BioMarin Pharmaceutical converted a competitive threat into a royalty-bearing asset, generating ongoing revenue from the arrangement. Conversion of competitive threat into royalty stream creates new long-term revenue and alters competitive positioning.

1 Sep

4 , 9:05 AM
BioMarin Pharmaceutical Inc. closed its acquisition of Alesta Therapeutics. Acquisition closure marks major strategic expansion altering BioMarin Pharmaceutical Inc. trajectory.

31 Aug

3 , 8:06 AM
BioMarin Pharmaceutical and Ascendis reached a mutually beneficial agreement ending all global patent disputes. Settlement ends patent litigation reducing legal costs and competitive uncertainties for BioMarin.

3 , 7:00 AM
BioMarin enters binding term sheet with Ascendis for global settlement and license agreement related to YUVIWEL® (Navepegritide). Settlement and license agreement may moderately affect BioMarin's operations and market position through resolved disputes and new licensing terms.

21 Aug

4 , 4:09 PM
BioMarin Pharmaceutical agrees to a $490 million deal for an oral rare bone disease program. The $490 million deal marks a major pipeline expansion in rare bone diseases via substantial strategic investment.

20 Aug

3 , 11:39 AM
BioMarin Pharmaceutical Q2 results are benchmarked against other therapeutics stocks on NASDAQ:BMRN. Q2 results benchmarking offers moderate insight into financial performance without indicating major strategic shifts.

19 Aug

4 , 6:02 PM
BioMarin Pharmaceutical enters Alesta deal to expand growth opportunities in rare diseases. Alesta deal strengthens BioMarin pipeline and long-term rare disease market position.

4 qz.com, 1:24 PM
BioMarin Pharmaceutical Inc. acquires Alesta Therapeutics for $275 million. The $275 million acquisition marks a major strategic expansion that can materially shift BioMarin's pipeline and long-term market position.

4 www.pharmaceutical-technology.com, 10:55 AM
BioMarin Pharmaceutical Inc. commits up to $490 million to acquire Alesta's bone disease candidate. Up to $490m deal for bone disease candidate marks major pipeline expansion with potential to shift BioMarin trajectory.

4 , 10:36 AM
BioMarin Pharmaceutical Inc. signs $490 million deal to acquire rare bone disease treatment. $490 million acquisition expands BioMarin portfolio with new rare disease asset and alters competitive positioning.

18 Aug

4 , 11:25 AM
BioMarin Pharmaceutical Inc. completed an Alesta deal that Wedbush analysts say will strengthen the company's long-term growth outlook. Alesta deal represents a major strategic move expected to significantly boost BioMarin Pharmaceutical's growth trajectory and investor sentiment.

4 investorshub.advfn.com, 9:41 AM
BioMarin Pharmaceutical acquires Alesta Therapeutics for $275 million, triggering a jump in its shares. The $275 million acquisition of Alesta Therapeutics represents a major strategic expansion that lifts BioMarin share prices.

4 , 8:30 AM
BioMarin acquires Alesta Therapeutics to secure ALE1, a potential first oral therapy for Hypophosphatasia, expanding its clinical pipeline. Acquisition adds first-in-class oral candidate and new clinical program that can materially shift BioMarin's rare-disease portfolio and growth outlook.

4 www.biopharmadive.com, 7:50 AM
BioMarin Pharmaceutical acquires experimental drug for rare bone disorder in $275M deal. Acquisition adds experimental asset to core rare-disease pipeline and may drive future revenue growth.

3 stocktwits.com, 1:36 PM
BioMarin Pharmaceutical stock rises after a deal with Alesta worth up to $490 million, but an analyst cuts the price target to $59. The large Alesta deal adds revenue potential while the price target cut highlights valuation risks that together produce moderate effects on company trajectory.

17 Aug

3 , 6:08 AM
BioMarin raised its 2026 outlook and filed an ESOP shelf offering, prompting questions on whether these moves strengthen the bullish case for BMRN shares. Raised 2026 guidance signals improved long-term visibility while the shelf offering adds potential equity issuance flexibility.

16 Aug

3 , 7:08 AM
BioMarin Pharmaceutical updated its financial guidance and filed a shelf registration. The actions prompt assessment of whether the stock remains below fair value. Guidance updates and shelf filings can shift near-term valuation and financing options without redefining core operations or long-term trajectory.

12 Aug

4 www.marketbeat.com, 10:05 AM
BioMarin targets accelerated debt reduction after completing an Amicus deal that broadens its rare-disease portfolio and growth outlook. Amicus acquisition accelerates deleveraging while expanding rare-disease revenue base and competitive position.

7 Aug

4 , 11:50 AM
BioMarin Pharmaceutical Inc. reported Q2 earnings that beat expectations on sales growth, lifting its stock price and leading to a raised 2026 outlook. Q2 earnings beat on sales growth combined with raised 2026 outlook points to stronger financial results and improved growth trajectory.

4 , 11:44 AM
BioMarin Pharmaceutical raised its 2026 outlook on strong Voxzogo sales, according to Wedbush. BioMarin raised 2026 outlook on strong Voxzogo sales indicating improved growth trajectory.

4 , 1:11 AM
BioMarin Pharmaceutical Inc reported record revenue in its Q2 2026 earnings call. Record revenue signals strong financial performance that can significantly lift investor sentiment and stock trajectory.

3 , 1:15 AM
BioMarin (BMRN) stock may exceed fair value after the ReNU Therapy deal. ReNU Therapy deal introduces valuation concerns that could moderately shift investor sentiment and short-term performance.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us